Dopamine oxidation generates an oxidative stress mediated by dopamine semiquinone and unrelated to reactive oxygen species.
Dopamine (100 microM, 10-30 min) inhibits/inactivates the MgATP-dependent generation of a transmembrane proton electrochemical gradient in chromaffin granule ghosts. The dopamine dependent inhibition was enhanced by adding soluble dopamine beta-monooxygenase (DBM, 0.2 U/ml) and completely prevented by ascorbate (1 mM), dithiothreitol (2 mM) and approximately 80% by the DBM inhibitor fusaric acid (10 microM). This indicates that the inhibition is caused by the dopamine semiquinone free radical generated during DBM-dependent dopamine oxidation. Catalase, superoxide dismutase or both did not prevent the inhibition, and DBM-catalysed dopamine oxidation did not change the basal level of lipid peroxidation, excluding the involvement of reactive oxygen species as being responsible for the inhibition. N-ethylmaleimide-sensitive ATPase activity (i.e. the proton translocating ATPase) in the vesicle membranes was inhibited during dopamine incubation, indicating that the toxic metabolite (dopamine semiquinone) inhibits proton pumping by inhibiting the endogenous vacuolar H(+)-ATPase. As this proton pump represents the driving force for the vesicular uptake and storage of catecholamines, the dopamine dependent inhibition, if taking place in vivo, may inhibit dopamine uptake in storage vesicles in sympathetic neurons, e.g. as observed in the myopathic hamster heart.
Terland
O
O
Department of Biochemistry and Molecular Biology, University of Bergen, Norway.
Flatmark
T
T
Tangerås
A
A
Grønberg
M
M
D000818:Animals; D001205:Ascorbic Acid / Q000494:pharmacology; D016227:Benzoquinones / Q000378:metabolism; D002374:Catalase / Q000494:pharmacology; D002417:Cattle; D019439:Chromaffin Cells / Q000187:drug effects / Q000378:metabolism*; D003634:DDT / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005292:Ferricyanides / Q000378:metabolism; D005669:Fusaric Acid / Q000494:pharmacology; D015227:Lipid Peroxidation; D008315:Malondialdehyde / Q000378:metabolism; D018384:Oxidative Stress / Q000502:physiology*; D054328:Proton Pump Inhibitors; D006180:Proton-Translocating ATPases / Q000187:drug effects / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism*; D013482:Superoxide Dismutase / Q000494:pharmacology; D014617:Vacuoles / Q000187:drug effects / Q000201:enzymology
D016227:Benzoquinones; D004791:Enzyme Inhibitors; D005292:Ferricyanides; D054328:Proton Pump Inhibitors; D017382:Reactive Oxygen Species; C025232:semiquinone radicals; D008315:Malondialdehyde; D003634:DDT; D002374:Catalase; D013482:Superoxide Dismutase; D006180:Proton-Translocating ATPases; D005669:Fusaric Acid; D001205:Ascorbic Acid; D004298:Dopamine